TBCRC45: AVIATOR: A Phase II Study Of Trastuzumab, Vinorelbine, and Avelumab ± PF-05082566 (4-1BB/CD137 Agonist) in HER2+ MBC
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Johns Hopkins University
Start Date
April 3, 2019
End Date
October 1, 2024
Administered By
Duke Cancer Institute
Awarded By
Johns Hopkins University
Start Date
April 3, 2019
End Date
October 1, 2024